At the presentation of KalVista Pharmaceuticals, Inc.‘s financial results for the first fiscal quarter ended 31 July 2021, CEO Andrew Crockett says:
“We have made excellent progress in the rollout of our Phase 2 Komplete clinical trial for KVD824. Site initiations are underway, and patients are being enrolled in the trial to evaluate KVD824 as a potential oral prophylactic treatment for HAE. We will be having an end-of-Phase 2 meeting with the FDA later this month regarding KVD900, our oral on-demand candidate for treatment of HAE attacks and are ready to initiate the Phase 3 study quickly afterwards. We look forward to advancing both of these compounds as we continue with our strategy of bringing a full spectrum of oral treatment options to HAE patients.”
(Source: KalVista)
